Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Fibrogen Inc Rises 6.45% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $46.58 to a high of $47.19. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $45.00...

FGEN : 47.45 (-1.27%)
FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List

FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA)....

FGEN : 47.45 (-1.27%)
Fibrogen Inc Rises 6.47% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $41.55 to a high of $44.20. Yesterday, the shares gained 6.5%, which took the trading range above the 3-day high of $41.00...

FGEN : 47.45 (-1.27%)
SmarTrend Watching for Potential Pullback in Shares of Fibrogen Inc After 1.19% Gain

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $36.46 to a high of $37.67. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $37.59...

FGEN : 47.45 (-1.27%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (NVTA , FGEN , INSM , ALKS , GBT )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

FGEN : 47.45 (-1.27%)
INSM : 22.74 (-2.36%)
NVTA : 16.67 (-5.93%)
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation...

FGEN : 47.45 (-1.27%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors who have suffered significant losses to submit their loss now to learn if they qualify to recover their investment losses. The firm is investigating...

FGEN : 47.45 (-1.27%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations...

FGEN : 47.45 (-1.27%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations...

FGEN : 47.45 (-1.27%)
SmarTrend Watching for Potential Rebound in Shares of Fibrogen Inc After 3.97% Loss

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.14 to a high of $35.69. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $34.35...

FGEN : 47.45 (-1.27%)
Fibrogen Inc is Among the Companies in the Biotechnology Industry with the Best Relative Performance (FGEN , NVTA , FOLD , SRPT , CYTK )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

FOLD : 9.40 (-3.89%)
FGEN : 47.45 (-1.27%)
NVTA : 16.67 (-5.93%)
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 47.45 (-1.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

FGEN : 47.45 (-1.27%)
FibroGen Reports Third Quarter 2019 Financial Results

-- Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney Week

FGEN : 47.45 (-1.27%)
FibroGen (FGEN) Soars: Stock Adds 9.6% in Session

FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

IRWD : 12.35 (-0.80%)
FGEN : 47.45 (-1.27%)
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+

FGEN : 47.45 (-1.27%)
Fibrogen Inc Falls 6.21% on Heavy Volume: Watch For Potential Rebound

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.35 to a high of $36.20. Yesterday, the shares fell 6.2%, which took the trading range below the 3-day low of $37.01...

FGEN : 47.45 (-1.27%)
FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease

FibroGen, Inc. (NASDAQ:FGEN), today announced results from the Phase 3 HIMALAYAS trial evaluating roxadustat for the treatment of anemia in incident dialysis (ID) patients with chronic kidney disease (CKD),...

FGEN : 47.45 (-1.27%)
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss

Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.

PTLA : 27.16 (-2.55%)
LCI : 8.81 (-0.56%)
FGEN : 47.45 (-1.27%)
MNK : 3.37 (+0.60%)
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales

Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.

IRWD : 12.35 (-0.80%)
DERM : 11.47 (+14.59%)
JAZZ : 148.37 (-1.13%)
FGEN : 47.45 (-1.27%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.72 , AIZ +0.03 , SBAC +0.10 , SO +0.25 , WELL -1.46
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar